MedTrace Logo

Efficacy of Lactobacillus Paracasei PS23 for Patients With Post-COVID-19 Syndrome

NCT05813899 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2024-08-15

No results posted yet for this study

Summary

To evaluate whether probiotics PS23 can improve the symptoms of patients with long COVID-19 ; also to evaluate the effects on blood cortisol and inflammation-related indicators in patients.

Conditions

  • Post-COVID-19 Syndrome

Interventions

DIETARY_SUPPLEMENT

PS23 heat-treated

PS23 heat-treated, 2 caps daily use

Sponsors & Collaborators

  • Bened Biomedical Co., Ltd.

    collaborator INDUSTRY

  • Mackay Memorial Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-16
Primary Completion
2023-12-31
Completion
2024-04-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05813899 on ClinicalTrials.gov